Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR ...

Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program for lead asset IMM-1-104 following favorable data against pancreatic cancer.

The Company's lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most ...

Matt Morgan is a Consultant in Intensive Care Medicine, Honorary Professor for the Public Understanding of Medicine and ...

wire [31:0] PC_Top,RD_Instr,RD1_Top,Imm_Ext_Top,ALUResult,ReadData,PCPlus4,RD2_Top,SrcB,Result; ...

wire [31:0] PC_Top,RD_Instr,RD1_Top,Imm_Ext_Top,ALUResult,ReadData,PCPlus4,RD2_Top,SrcB,Result; ...

Now, 25 years later, more than 100 of his former patients have some vindication in their yearslong fight: a court has ordered him to pay a total of $1.6 billion ... The last of the 104 awards ...

licence approval submitted 280 days ago , due any day now ( facts in my history ) 1,5 billion tones of Nickel ... No mean feat when both IMM & SCGL have tanked from the level you were ramping ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...